Elevance Health - Q1 2026 Earnings Analysis

Performance Highlights

Elevance Health reported first quarter 2026 operating revenue of $49.5 billion, up 1.5% year over year, with adjusted diluted EPS of $12.58 versus $11.97 in the prior-year period, surpassing consensus expectations. The beat was driven by underlying business strength, favorable ACA seasonality, and approximately $1.00 per share of non-recurring net investment income, with operating cash flow surging to $4.3 billion, up $3.3 billion year over year.

The single most important operating driver was improving claims experience in Medicare Advantage, which partially offset persistently elevated Medicaid cost trends that pushed the benefit expense ratio 40 basis points higher to 86.8%. Carelon posted 7.9% revenue growth to $18.0 billion on scaling risk-based solutions and CarelonRx product revenue, while the adjusted operating expense ratio tightened 20 basis points to 10.5%, reflecting disciplined cost management across the enterprise.

Management Outlook and Forward Catalysts

Management raised full-year 2026 adjusted diluted EPS guidance to at least $26.75, anchored to a $25.75 earnings baseline that excludes the non-recurring investment income, and reaffirmed operating cash flow of at least $5.5 billion inclusive of potential CMS matter cash payments. The guidance raise signals growing confidence in cost trend stabilisation and pricing discipline, with the company also targeting a return to at least 12% adjusted diluted EPS growth in 2027 off the revised baseline.

The central investor debate centres on resolution and ultimate financial exposure of the $935 million CMS Medicare Advantage risk adjustment accrual, alongside the pace of Medicaid margin recovery as redeterminations and cost interventions play out. Bulls will focus on the faster-than-expected Medicare claims improvement and Carelon's high-teens revenue growth trajectory, while bears will monitor whether Medicaid cost trends reaccelerate and whether the 15.8% year-over-year decline in Medicare Advantage membership proves a structural headwind to long-term earnings power.